The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

Vitamin A is fat-soluble and can build up in the body. This can lead to dry skin, blurry vision, bone problems and liver damage. In pregnant women, it can even cause birth defects. Dr Lesley Motheral, ...

Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

Licensing criteria should be equitable, nondiscriminatory, objective, and compatible with similar risks in other populations.

HealthDay News — Combination lipid-lowering therapy (LLT) is associated with a greater reduction in low-density lipoprotein cholesterol (LDL-C) compared with statin monotherapy, according to a study ...

HealthDay News — With a new law, signed by Gov. Spencer Cox on March 27, Utah has become the first US state to ban the addition of fluoride to public drinking water, The New York Times reported. The ...

The Company claims the sponge powder exfoliates the skin, promotes collagen production, and opens closed comedones.

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

The approval of iptacopan in reducing proteinuria in adult patients with native kidney C3G was based on data from the randomized, double-blind, placebo-controlled, phase 3 APPEAR-C3G trial.

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).